Date of submission of the HTAC Recommendation: 01 June 2026Date of notification to HTAC on the SOH decision: 21 September 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on (1) Paroxetine [20 mg tablet and 20 mg film-coated tablet] and (2) Vortioxetine [5mg, 10mg, 15mg, 20mg film-coated tablet] continue reading : HTA Council Final Recommendation Paroxetine (20 mg tablet and 20 mg film-coated tablet) and Vortioxetine (5 mg, 10mg, 15mg, 20mg film-coated tablet) for the treatment of mental health conditions
HTA Council Final Recommendation on Iopromide 623.40 mg/mL and 768.86 mg/mL in 500 mL clear glass infusion bottle for use as contrast media
Date of submission of the HTAC Recommendation: 14 May 2026Date of notification to HTAC on the SOH decision: 17 August 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on Iopromide (1) 623.40 mg/mL (equivalent to 300 mg iodine) and (2) 768.86 mg/mL (equivalent to 370 mg iodine) in continue reading : HTA Council Final Recommendation on Iopromide 623.40 mg/mL and 768.86 mg/mL in 500 mL clear glass infusion bottle for use as contrast media
HTA Council Final Recommendation on Pneumococcal Vaccines for the Prevention of Diseases caused by Streptococcus pneumoniae in Adults 60 years old and above (with Secretary of Health Decision)
Date of submission of the HTAC Recommendation: 27 March 2026Date of notification to HTAC on the SOH decision: 18 June 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on pneumococcal vaccines for the prevention of diseases caused by Streptococcus pneumoniae in elderly adults 60 years old and above, continue reading : HTA Council Final Recommendation on Pneumococcal Vaccines for the Prevention of Diseases caused by Streptococcus pneumoniae in Adults 60 years old and above (with Secretary of Health Decision)
HTA Council Final Recommendation on Multiple Micronutrient Supplement (MMS) film-coated tablet for the prevention of vitamin and mineral deficiencies, improvement of iron status, and reduction of anemia among pregnant and lactating women (with Secretary of Health Decision)
Date of submission of the HTAC Recommendation: 13 February 2026Date of notification to HTAC on the SOH decision: 02 June 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on multiple micronutrient supplement (MMS) film-coated tablet for the prevention of vitamin and mineral deficiencies, improvement of iron status, and continue reading : HTA Council Final Recommendation on Multiple Micronutrient Supplement (MMS) film-coated tablet for the prevention of vitamin and mineral deficiencies, improvement of iron status, and reduction of anemia among pregnant and lactating women (with Secretary of Health Decision)
HTA Council Final Recommendation on Epidermal Growth Factor Receptor (EGFR) Polymerase Chain Reaction (PCR) mutation test for the diagnosis of EGFR Mutations in patients with Non-Small Cell Lung Cancer (NSCLC) (with Secretary of Health Decision)
Date of submission of the HTAC Recommendation: 18 March 2026Date of notification to HTAC on the SOH decision: 07 May 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on Epidermal Growth Factor Receptor (EGFR) Polymerase Chain Reaction (PCR) Mutation Test for the diagnosis of EGFR mutations in patients continue reading : HTA Council Final Recommendation on Epidermal Growth Factor Receptor (EGFR) Polymerase Chain Reaction (PCR) mutation test for the diagnosis of EGFR Mutations in patients with Non-Small Cell Lung Cancer (NSCLC) (with Secretary of Health Decision)